Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Full-length recombinant human MAGE-A.|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor-directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). An important group of antigens is coded by the MAGE family of genes. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.
35-6300 was used in western blot to investigate the effect of SGI-110 on cancer testis antigen gene-regulated expression
|Srivastava P,Paluch BE,Matsuzaki J,James SR,Collamat-Lai G,Karbach J,Nemeth MJ,Taverna P,Karpf AR,Griffiths EA||Leukemia research (38:1332)||2014|
|Human||1:500||Expression of family A melanoma antigen in human gastric carcinoma.||Jung EJ,Kim MA,Lee HS,Yang HK,Lee YM,Lee BL,Kim WH||Anticancer research (25:2105)||2005|
|Human||Not Cited||Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy.||Akcakanat A,Kanda T,Tanabe T,Komukai S,Yajima K,Nakagawa S,Ohashi M,Hatakeyama K||International journal of cancer (118:123)||2006|
Antigen MZ2-E; Cancer/testis antigen 1.1; cancer/testis antigen family 1, member 1; CT1.1; MAGE-1 antigen; MAGE1A; MAGEA1; melanoma antigen family A 1; melanoma antigen family A, 1 (directs expression of antigen MZ2-E); melanoma antigen family A1; melanoma antigen MAGE-1; Melanoma-associated antigen 1; melanoma-associated antigen MZ2-E
CT1.1; MAGE1; MAGE1A; MAGEA1